Lecture Notes

**Lecture Coverage:**
- Drug Metabolism
- Phase of Liver Drug Biotransformation
- Factors Affecting Drug Biotransformation

---
#### **Drug Metabolism**
**Fate of Drugs after Biotransformation**
- Activation of Prodrugs
	- Prodrugs have ↑ Stability & ↓ Side effects during Distribution
- Extraction of Active Metabolite from Active Drug
- Inactivation of Active Metabolites into Less Active Products



#### **Phase of Liver Drug Biotransformation**

|                     **Phase**                     |     **Phase**     | **Description**                                                                                                                    | **Reactions**                                                       |
| :-----------------------------------------------: | :---------------: | ---------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------- |
|                         I                         | Functionalization | Add a functional group handle to drugs<br>→ More susceptible to phase II                                                           | Redox (e.g. Monooxygenation by CYP450)<br>Hydrolysis                |
|                      <br>II                       |  <br>Conjugation  | Conjugation with endogenous substrate → Facilitate Excretion:<br>∵ ↑ Polarity<br>∵ ↑ Molecular weight (favors bile excretion)      | Glucuronide conjugation (by UGT)<br>- Becomes Drug-Glucuronide (DG) |
| Enterohepatic<br>Circulation<br>(Some Drugs only) |         <         | Some bile DG travel to gut lumen →<br>Deconjugated into free drug by bacteria → Reabsorbed back to liver<br>→ Prolongs drug action | Deconjugation (by β glucuronidase)                                  |


#### **Sites of Biotransformation**
**Enzymes**
- Microsomal & Non-microsomal:

| Properties             | <        | Microsomal Enzymes                                                                         | Non-Microsomal Enzymes      |
| ---------------------- | -------- | ------------------------------------------------------------------------------------------ | --------------------------- |
| Location               | <        | Liver & Other Tissue Smooth ER                                                             |                             |
| <br>Reactions Involved | Phase I  | Oxidation (<abbr Title="Cytochrome P 450 Isoenzyme Superfamily">CYP450</abbr>), Hydrolysis | Redox, Hydrolysis           |
| ^                      | Phase II | Glucuronide Conjugation (<abbr Title="UDP-Glucuronosyl Transferase">UGT</abbr>)            | Non-Glucuronide Conjugation |
| Induced by Drugs       | <        | Yes                                                                                        | No                          |
| Genetic Polymorphism   | <        | Yes                                                                                        | Yes                         |

**Hoffmann Elimination**
- Inactivation of drug in body fluid:
	- Through Spontaneous Molecular Arrangement
	- Without Enzyme Catalysis
- e.g. Atracurium (Skeletal Muscle Relaxant)



#### **Factors Affecting Drug Biotransformation**
**Drug-Drug Interactions**
- Enzyme Inhibition: Different Drugs share same isoenzyme as Substrate / Inhibitor
	- ↓ Oral metabolism → ↑ Bioavailability
	- ↓ Liver Biotransformation → ↓ Clearance → Toxicity
	- E.g. Quinidine: 3A4 Substrate & 2D6 Inhibitor
- Enzyme Induction:
	- Drug interacts with DNA → ↑ UGT & CYP450 synthesis (4-14 days) → ↑ Metabolism & ↓ Drug Response
	- E.g. Phenobarbitone induces Warfarin-metabolizing enzymes
		- Required to ↑ Warfarin Dose if Phenobarbitone & Warfarin Concomitant Administration
	- E.g. Rifampicin induces <abbr Title="Oral Contraceptive Pills">OCP</abbr>-metabolizing enzymes
		- Contraceptive Failure if Rifampicin & OCP Concomitant Administration

**Pharmacogenetics**
- Individual / Conb